Nation

Bharat Biotech and ICMR Announce Interim Results from Phase 3 trials of COVAXIN®; Demonstrates overall Interim Clinical Efficacy of 78% and 100% efficacy against Severe COVID-19 disease

Hyderabad, India, April 21, 2021: Bharat Biotech, a global leader in vaccine innovation, developing vaccines for infectious diseases, announced phase 3...